Williams L T, Mullikin D, Lefkowitz R J
J Biol Chem. 1976 Nov 25;251(22):6915-23.
[3H]Dihydroergocryptine, a potent alpha-adrenergic antagonist, was used to label smooth muscle membrane binding sites which have the characteristics expected of alpha-adrenergic receptors. Binding of [3H]dihydroergocryptine to rabbit uterine membranes was rapid and reversible with rate constants of 1.26 X 10(7) M-1 min-1 and 0.034 min-1 for the forward and reverse reactions, respectively. [3H]Dihydroergocryptine binding was of high affinity, with an equilibrium dissociation constant (KD) of 8 to 10 nM. Binding was saturable with 0.14 to 0.17 pmol of [3H]dihydroergocryptine bound/mg of protein at maximal occupancy of the sites. No cooperative interactions among the sites were detected. The specificity of the binding sites for a large number of adrenergic agonists and antagonists was identical with the specificity of alpha-adrenergic responses to these agents. The alpha-adrenergic agonist (-)-epinephrine competed for binding with a KD of 0.23 muM. The order of potencies for several adrenergic agonists in competing for the binding sites was (-)-epinephrine greater than (-)-norepinephrine greater than (-)-phenylephrine greater than (-)-isoproterenol in agreement with their alpha-adrenergic potencies. A series of 19 phenylethylamine adrenergic agonists competed for binding in a manner paralleling their potencies as alpha-adrenergic agonists. alpha-Adrenergic antagonists such as phentolamine (KD = 15 nM) and phenoxybenzamine (KD = 18 nM) potently competed for the binding sites. In contrast, beta-adrenergic antagonists such as propranolol (KD = 27,000 nM) and practolol (KD greater than 10(6) nM) did not have high affinity for the binding sites. A series of ergot alkaloids competed for [3H]dihydroergocryptine binding in a manner which paralleled their potencies as alpha-adrenergic agents. Competition for binding sites by alpha-adrenergic agonists and antagonists was a stereospecific process. The (-)-stereoi somers of epinephrine, norepinephrine, and ergotamine were at least 20- to 50-fold more potent than the corresponding (+)-stereoisomers. Compounds devoid of significant alpha-adrenergic activity, such as pyrocatechol, 3,4-dihydroxymandelic acid, normetanephrine, and D-lysergic acid, did not effectively compete for [3H]dihydroergocryptine binding sites. These rabbit uterine binding sites for [3H]dihydroergocryptine appear to have characteristics indistinguishable from those of the physiologically active alpha-adrenergic receptors.
[3H]二氢麦角隐亭是一种强效α-肾上腺素能拮抗剂,用于标记具有α-肾上腺素能受体预期特征的平滑肌膜结合位点。[3H]二氢麦角隐亭与兔子宫膜的结合迅速且可逆,正向和反向反应的速率常数分别为1.26×10(7)M-1min-1和0.034min-1。[3H]二氢麦角隐亭的结合具有高亲和力,平衡解离常数(KD)为8至10nM。在位点最大占据时,每毫克蛋白质结合0.14至0.17pmol的[3H]二氢麦角隐亭时结合达到饱和。未检测到位点之间的协同相互作用。大量肾上腺素能激动剂和拮抗剂的结合位点特异性与这些药物的α-肾上腺素能反应特异性相同。α-肾上腺素能激动剂(-)-肾上腺素以0.23μM的KD竞争结合。几种肾上腺素能激动剂竞争结合位点的效力顺序为(-)-肾上腺素>(-)-去甲肾上腺素>(-)-苯肾上腺素>(-)-异丙肾上腺素,与其α-肾上腺素能效力一致。一系列含有19种苯乙胺的肾上腺素能激动剂以与其作为α-肾上腺素能激动剂的效力平行的方式竞争结合。α-肾上腺素能拮抗剂如酚妥拉明(KD = 15nM)和酚苄明(KD = 18nM)强烈竞争结合位点。相比之下,β-肾上腺素能拮抗剂如普萘洛尔(KD = 27,000nM)和普拉洛尔(KD>10(6)nM)对结合位点没有高亲和力。一系列麦角生物碱以与其作为α-肾上腺素能药物的效力平行的方式竞争[3H]二氢麦角隐亭的结合。α-肾上腺素能激动剂和拮抗剂对结合位点的竞争是一个立体特异性过程。肾上腺素、去甲肾上腺素和麦角胺的(-)-立体异构体的效力比相应的(+)-立体异构体至少高20至50倍。缺乏显著α-肾上腺素能活性的化合物如儿茶酚、3,4-二羟基扁桃酸、去甲变肾上腺素和D-麦角酸不能有效竞争[3H]二氢麦角隐亭的结合位点。这些兔子宫中[3H]二氢麦角隐亭的结合位点似乎具有与生理活性α-肾上腺素能受体无法区分的特征。